EP1425287A1 - Procedes permettant de preparer des formes salines calciques de statines - Google Patents

Procedes permettant de preparer des formes salines calciques de statines

Info

Publication number
EP1425287A1
EP1425287A1 EP02759374A EP02759374A EP1425287A1 EP 1425287 A1 EP1425287 A1 EP 1425287A1 EP 02759374 A EP02759374 A EP 02759374A EP 02759374 A EP02759374 A EP 02759374A EP 1425287 A1 EP1425287 A1 EP 1425287A1
Authority
EP
European Patent Office
Prior art keywords
statin
calcium
atorvastatin
protecting group
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02759374A
Other languages
German (de)
English (en)
Other versions
EP1425287A4 (fr
Inventor
Valerie Niddam-Hildesheim
Revital Lifshitz-Liron
Rami Lidor-Hadas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/037,412 external-priority patent/US6528661B2/en
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1425287A1 publication Critical patent/EP1425287A1/fr
Publication of EP1425287A4 publication Critical patent/EP1425287A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to processes for preparing calcium salt forms of statins.
  • statins are currently the most therapeutically effective drugs available for reducing low-density lipoprotein (LDL) particle concentration in the blood stream of patients at risk for cardiovascular disease and thus, statins are used in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
  • LDL low-density lipoprotein
  • HMG-CoA reductase catalyzes the conversion of HMG to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. Decreased production of cholesterol causes an increase in the number of LDL receptors and corresponding reduction in the concentration of LDL particles in the bloodstream. Reduction in the LDL level in the bloodstream reduces the risk of coronary artery disease. J.A.M.A. 1984, 251, 351-74.
  • statins include lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin and atorvastatin.
  • Lovastatin (disclosed in U.S. Pat. No. 4,231,938) and simvastatin (ZOCOR; disclosed in U.S. Pat. No. 4,444,784 and WO 00/53566) are administered in the lactone form. After absorption, the lactone ring is opened in the liver by chemical or enzymatic hydrolysis, and the active hydroxy acid is generated.
  • Pravastatin PRAVACHOL; disclosed in U.S. Pat. No. 4,346,227) is administered as the sodium salt.
  • Fluvastatin (LESCOL; disclosed in U.S. Pat. No.
  • cerivastatin (disclosed in U.S. Pat. No. 5,006,530 and 5,177,080), also administered as the sodium salt, are entirely synthetic compounds that are in part structurally distinct from the fungal derivatives of this class that contain a hexahydronaphthalene ring. Atorvastatin and two new "superstatins,” rosuvastatin and pitavastatin, are administered as calcium salts. The structural formulas of these statins are shown below.
  • Atorvastatin is the common chemical name for [R-(R * , R * )]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-l- heptanoic acid.
  • the free acid of atorvastatin is prone to lactonization.
  • atorvastatin lactone is (2R-trans)-5-(4-fluorophenyl)-2-(l-methylethyl)- N,4-diphenyl- 1 - [2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl] - 1 H-pyrrole-3- carboxamide.
  • Atorvastatin and its corresponding racemic lactone are disclosed in U.S. Patent No. 4,681,893.
  • the lactone form is disclosed in U.S. Patent No. 5,273,995.
  • the lactone is prepared by dissolving 1,1-dimethylethyl (R)-7-[2-(4- fluorophenyl)-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrol-l-yl]-5- hydroxy-3-oxo-l-heptanoate in tetrahydrofuran and triethyl borane, followed by the addition of t-butylcarboxylic acid. After cooling, methanol is added followed by sodium borohydride. The mixture is poured into an ice/hydrogen peroxide/water mixture.
  • Trichloromethane is added and the mixture is partitioned.
  • the organic layer is dried over magnesium sulfate, filtered, and the solvent is evaporated.
  • the product is dissolved in tetrahydrofuran and methanol and added to a solution of sodium hydroxide.
  • the mixture is concentrated to remove organic solvent, added to water, and extracted with diethyl ether.
  • the aqueous layer is acidified with hydrochloric acid and extracted with ethyl acetate.
  • the organic layer is dried with anhydrous magnesium sulfate, filtered, and the solvent evaporated.
  • the residue is dissolved in toluene and concentrated.
  • the product is recrystallized from ethyl acetate and hexane to produce the lactone.
  • the lactone can also be prepared according to the procedures disclosed in U.S.
  • Patent No. 5,00 ⁇ ,080 For instance, in Example 2, Method A, cis-2-(4-Fluorophenyl)- ⁇ , ⁇ - dihydroxy-5-(l-methylethyl)-3-phenyl-4-(phenylamino)carbonyl-lH-pyrrole-l-heptanoic acid, methyl ester is treated with sodium hydroxide, and after dilution with water and separation, the remaining layer are washed with hexane and ethyl acetate followed by concentrated hydrochloric acid solution. Upon separation, the upper layer is washed with hydrochloric acid and concentrated. The residue is dissolved in toluene.
  • the lactone can also be prepared by mixing ( ⁇ )-cis- 6-(2-aminoethyl)-2,2-dimethyl-l,3-dioxane-4-acetic acid (Example 2, Method B); ( ⁇ )- (2 ⁇ ,4 ⁇ ,6 ) or ( ⁇ )-(2 ,4 ⁇ ,6 ⁇ )-6-(2-aminoethyl)-2-phenyl-l,3-dioxane-4-acetic acid (Example 2, Method C); ( ⁇ )-cis-9-(2-aminoethyl)-6,10-dioxaspiro[4.5]decane-7-acetic acid (Example 2, Method D); ( ⁇ )-cis-(4-(2-aminoethyl)-l,5-dioxaspiro[5.5]undecane-2- acetic acid (Example 2, Method E); or ( ⁇ )-(2 ⁇ ,4 ⁇ ,6 ) or
  • the solution is poured into a mixture of diethyl ether and saturated ammonium chloride in water. After separation, the organic layer is washed with water and sodium hydroxide. The aqueous layer is acidified with dilute hydrochloric acid and extracted with ethyl acetate, to which hydrochloric acid is added, and the solution is concentrated. The residue is dissolved in toluene.
  • Another method of making the lactone includes mixing ( ⁇ )-cis 1 , 1 -dimethylethyl-6-(2-aminoethyl)-2,2-dimethyl- 1 ,3-dioxane-4-acetate (Example 2, Method H); ( ⁇ )-(2 ⁇ ,4 ⁇ ,6 ⁇ ) or ( ⁇ )-(2 ,4 ⁇ ,6 ⁇ )-l,l-dimethyl-6-(2- aminoethyl)-2-phenyl-l,3-dioxane-4-acetate (Example 2, Method I); or ( ⁇ )-cis-l,l- dimethylethyl (4-(2-aminoethyl)-l,5-dioxaspiro[5.5]undecane-2-acetate (Example 2, Method J) with ( ⁇ )4-fluoro- ⁇ -[2-methyl-l-oxopropyl]- ⁇ -oxo-N, ⁇ -dip
  • the lactone or the free acid may be used to prepare the pharmaceutically acceptable calcium salt, [R-(R*,R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-(l-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-l-heptanoic acid calcium salt (2:1) trihydrate.
  • atorvastatin calcium salt has been shown to lower plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver.
  • Atorvastatin is marketed by PFIZER as the hemicalcium salt trihydrate under the trade name LIPITOR, as 10, 20, 40 and 80 mg tablets.
  • Atorvastatin hemicalcium salt has the following structure:
  • the hemicalcium salt is disclosed in U.S. Patent No. 5,273,995, which teaches that the calcium salt is obtained by crystallization from a brine solution resulting from the transposition of the sodium salt with calcium chloride and further purified by recrystallization from a 5:3 mixture of ethyl acetate and hexane.
  • U.S. Patent No. 5,298,627 also discloses a process for making the hemicalcium salt.
  • (4R-cis)-l-[2-[6-[2-(diphenylamino)-2-oxoethyl]-2,2- dimethyl-l,3-dioxan-4-yl]ethyl]-5-(4-fluorophenyl)-2-(l-methylethyl)-N,4-diphenyl-lH- pyrrole-3-carboxamide is dissolved in methanol and reacted with hydrochloric acid to form [R-(R*,R*)]-5-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-2-(l-methylethyl)-N,N,4-triphenyl-3- [(phenylamino)carbonyl]-lH-pyrrole-l-heptanamide, which is mixed with methanol and sodium hydroxide.
  • the filtrate is washed with tert-butyl methyl ester and the aqueous layer is acidified using aqueous hydrochloric acid and extracted with tert-butyl methyl ester to form the sodium salt of [R-(R*,R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-(l- methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-l-heptanoic acid.
  • the sodium salt is converted to the hemicalcium salt by the addition of calcium acetate in water.
  • (4R-cis)-6-(2-aminoethyl)-2,2-dimethyl-N,N- bis(phenylmethyl)-l,3-dioxane-4 -acetamide is converted to [R-(R*,R*)]-5-(4- fluorophenyl)- ⁇ , ⁇ -dihydroxy-2-(l-methylethyl)-4-phenyl-3-[(phenylamino)carbonyl]- N,N-bis(phenylmethyl)-lH-pyrrole-l-heptanamide which is further converted to the hemicalcium salt (Example 2);
  • (4R-cis)-6-(2-aminoethyl)-N,N-diethyl-2,2-dimethyl-l,3- dioxane-4-acetamide is converted to [R-(R*,R*)]-N,N-diethyl-5-(4-fluorophenyl)- ⁇ , ⁇ -
  • Rosuvastatin is the common chemical name for [S-[R * ,S * -(E)]]-7-[4-(4- fluorophenyl)-6-(l-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5- dihydroxy-6-heptenoic acid. Rosuvastatin is in the process of being approved for marketing under the name CRESTOR, which contains rosuvastatin calcium. Rosuvastatin, its calcium salt (2:1), and its lactone form are disclosed and claimed in U.S. Patent No. 5,260,440.
  • rosuvastatin by reacting 4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5- pyrimidinecarbardehyde with methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate in acetonitrile under reflux.
  • the silyl group is then cleaved with hydrogen fluoride, followed by reduction with NaBH 4 to obtain a methyl ester of rosuvastatin.
  • the ester is then hydrolyzed with sodium hydroxide in ethanol at room temperature, followed by removal of ethanol and addition of ether, to obtain the sodium salt of rosuvastatin.
  • the sodium salt is then converted to the calcium salt with a multi-step process.
  • the sodium salt is dissolved in water and maintained under a nitrogen atmosphere.
  • Calcium chloride is then added to the solution, resulting in precipitation of rosuvastatin calcium (2:1).
  • U.S. Pat. No. 6,316,460 discloses a pharmaceutical composition of rosuvastatin.
  • the pharmaceutical compositions contain rosuvastatin or its salt and a multivalent tribasic phosphate salt.
  • the '460 patent does not disclose any methods for preparing the calcium salt of rosuvastatin.
  • Pitavastatin is the common chemical name for (E)-3,5-dihydroxy-7-[4'-(4"- fluorophenyl)-2'-cyclopropyl-quinolin-3'-yl]-hept-6-enoic acid.
  • Pitavastatin, its calcium salt (2:1), and its lactone are disclosed in three related U.S. Pat. Nos. 5,011,930, 5,856,336 and 5,872,130.
  • the '930 patent prepares pitavastatin ethyl ester in accordance with Example 1.
  • First 4-(4'-fluorophenyl-2'-(l '-cyclopropyl)-quinolin-3'-yl-carboxylate is prepared by reacting 2-amino-4'-fluorobenzophenone with ethyl isobutyrylacetate, which is then converted to 4-(4'-fluorophenyl)-3-hydroxymethyl-2-(r-cyclopropyl)-quinoline, which is converted to 4-4'-fluorophenyl-2-(r-cyclopropyl)-quinolin-3'-yl-carboxyaldehyde, which is converted to 3-(3'-ethoxy- -hydroxy-2'-propenyl)-4-(4'-fluorophenyl)-2-( cyclopropyl)-quinoline, which is converted to (E)-3-[4'-(4"-fluorophenyl)-2
  • the resulting ester, ethyl (E)-3,5-dihodroxy-7-[4'-(4"-fluorophenyl)-2'-(l"- cyclopropyl)-quinolin-3'-yl]-hept-6-enoate, is converted to the sodium salt in accordance to Example 2 by using an aqueous solution of sodium hydroxide.
  • the compound is dissolved in ethanol, to which an aqueous solution of sodium hydroxide is added.
  • the resulting mixture is stirred and the ethanol is removed under reduced pressure. Water is then added, and the mixture is further extracted with ether.
  • the aqueous layer is then lyophilized to obtain the final product, or the aqueous layer is weakly acidified with a dilute solution of hydrochloric acid.
  • the acidified aqueous layer is then extracted with ether. After extraction, the ether layer is dried over magnesium sulphate. Then the ether is removed under reduced pressure to obtain the sodium salt.
  • the '930 patent and its related patents do not disclose preparing the calcium salt of any compound.
  • U.S. Pat. No. 6,335,449 improves the prior art process for preparing pitavastatin by reacting an aldehyde quinoline with diethyl cyanomthylphosphonate to obtain a nitrile intermediate for the synthesis of pitavastatin.
  • U.S. Pat. No. 6,335,449 does not disclose how to prepare the calcium salt or any other salt of pitavastatin.
  • Simvastatin is the common medicinal name of the chemical compound butanoicacid,2,2-dimethyl-, 1,2, 3,7,8, 8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydro xy-6- oxo-2H-pyran-2-yl)-ethyl]-l-naphthalenyl ester, [lS*-[la,3a,7b,8b(2S*,4S),-8ab]]. (CAS Registry No. 79902-63-9.). Simvastatin is marketed as ZOCOR, and is disclosed in U.S. Patent Nos. 4,444,784 and 6,002,021, as well as WO 00/53566. These references disclose preparing the lactone, and the open form of simvastatin.
  • WO 00/53566 discloses preparing the calcium salt of the open form of simvastatin.
  • the process of WO 00/53566 hydrolyzes the lactone of simvastatin with sodium hydroxide, followed by addition of a calcium source, such as calcium acetate hydrate.
  • the present invention provides a novel process for preparing statin calcium salts having the formula:
  • R represents an organic radical, comprising contacting an ester derivative of the statin selected from the group consisting of:
  • Ri is a to a C 8 alkyl group
  • R 2 , R 3 and R each independently represent hydrogen, or the same or different hydrolyzable protecting group, or R 2 and R 3 , together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group.
  • phase transfer catalysts are quaternary ammonium salts such as tetrabutylammonium bromide (TBAB) and triethylbenzylammonium chloride (TEBA).
  • TBAB tetrabutylammonium bromide
  • TEBA triethylbenzylammonium chloride
  • Preferred statins are atorvastatin, rosuvastatin, pitavastatin and simvastatin.
  • R 2 , R and j are hydrogen.
  • Each of R 2 , R or Rj can also be the same or different protecting group, which are hydrolyzed by use of calcium hydroxide in one step together with hydrolysis of the ester group, i.e., -COORi, or hydrolyzed by using an acid catalyst, followed by hydrolysis of the ester group -COORi.
  • Preferred protecting groups are silyl groups such as trialkylsilyl, which can be hydrolyzed by calcium hydroxide, and acetonide, which can be hydrolyzed by an acid catalyst. Acetonide forms a cyclic hydrolyzable protecting group, i.e., a dioxane.
  • the present invention provides a process for preparing a calcium salt of a statin having the formula:
  • R represents an organic radical
  • Forming an ester is a well known way of protecting a carboxylic acid group and masking its acidic proton. Green, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis 3rd. ed., chapter 5 (John Wiley & Sons: New York 1999) ("Greene & Wuts"). It is also known, generally, that carboxylic acids that have been protected as esters may be deprotected by hydrolyzing the ester with a strong base. Id. at 377-78.
  • an "ester derivative” is a compound resulting from replacement of the hydroxyl proton of the carboxylic acid group in the ring-opened or dihydroxy acid form of the statin with a substituent bonded to the hydroxyl oxygen atom through carbon.
  • ester derivatives include, e.g., compounds wherein the substituent bonded to the hydroxyl oxygen of the carboxylic acid is a C ⁇ -C 8 alkyl group.
  • the ester derivative used for conversion can be a mixture of derivatives containing various esters. For example, a methyfester derivative can be added to ethanol, resulting in the conversion of some of the methyl esters to ethyl esters.
  • the ester derivative of the statin can be produced by methods known in the art or can be purchased commercially.
  • An ester derivative also includes the lactone or closed-ring form of the statin.
  • the lactone form is a cyclic ester in which the ester group of the statin is incorporated into the ring.
  • a mixture of ester derivatives also includes a mixture of the open- and closed-ring forms of the statin.
  • the present invention is directed to statins having the general formula:
  • statins include, e.g., pravastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, pitavastatin, lovastatin and simvastatin. Of these, atorvastatin, rosuvastatin, pitavastatin and simvastatin are preferred.
  • R refers to an organic radical that is bonded to the diol pentanoic acid group.
  • the R radical can be: pravastatin: l,2,6,7,8,8a-Hexahydro-6-hydroxy-2-methyl-8-(2-methyl-l-oxobutoxy)-l- naphthalene ethyl radical.
  • fluvastatin 3-(4-fluorophenyl)- 1 -( 1 -methylethyl)- 1 H-indol-2-yl] -ethylene radical
  • cerivastatin 4-(4-fluorophenyl)-5-methoxymethyl)-2,6bis(l-methylethyl)-3-pyridinyl- ethylene radical.
  • atorvastatin 2-(4-fluorophenyl)-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]- lH-pyrrole-ethyl radical
  • rosuvastatin [4-(4-fluorophenyl)-6-(l-methylethyl)-2-[methyl(methylsulfonyl)amino]-5- pyrimidinyl]-ethylene radical.
  • pitavastatin [4'-(4"-fluorophenyl)-2'-cyclopropyl-quinolin-3 '-yl]-ethylene radical.
  • the R radical can also be that of the open ring form, i.e., the dihydroxy acid, of simvastatin or lovastatin. These open ring forms also have a diol pentanoic acid group.
  • simvastatin and lovastatin include both the lactone form and the open-ring form.
  • the R radical is: simvastatin: 1 ,2,6,7,8, 8a-Hexahydro-2,6-dimethyl-8-(2,2-dimethyl-l -oxobutoxy)-l - naphthalene ethyl radical.
  • lovastatin 1, 2,6,7,8, 8a-Hexahydro-2,6-dimethyl-l-8-(2 -methyl- l-oxobutoxy)-l- naphthalene ethyl radical.
  • the calcium salt of these and other statins can be made by the processes of the present invention such that the organic radical bonded to the diol pentanoic acid group or corresponding lactone, defines a compound that is a statin, i.e., a compound that inhibits 3- hydroxy-3-methyl-glutaryl-coenzyme A (“HMG-CoA”) reductase enzyme.
  • HMG-CoA 3- hydroxy-3-methyl-glutaryl-coenzyme A
  • R should not be construed as limited to the organic radical bonded to the diol pentanoic acid group or corresponding lactone of the statins expressly disclosed or exemplified herein. All hydrates, solvates and anhydrates of the calcium salt and other polymorphic forms thereof, crystalline or amorphous, of these statins are within the scope of the present invention.
  • the present invention illustrates preparation of calcium salt of these statins by using preparation of atorvastatin hemi-calcium as an example.
  • preparation of atorvastatin hemi-calcium is different than that for another statin, one of skill in the art would appreciate that atorvastatin is being used merely for illustrative purposes; and that the various aspects in the preparation of atorvastatin hemi-calcium can be readily modified to prepare the other statins, while still being within the spirit and scope of the present invention.
  • the present invention provides a process for preparing a statin hemi-calcium salt by converting a statin ester derivative of formula:
  • R represents an organic radical and Ri is a Ci to C 8 alkyl group, to the corresponding hemi-calcium salt having the formula:
  • a "sufficient amount” as used herein refers to the amount of calcium hydroxide that substantially converts the ester derivative to the corresponding hemi-calcium salt.
  • substantially converts as used herein is meant an amount such that greater than about 50% (molar basis), preferably greater than about 70%, and more preferably greater than about 90%) of the statin ester derivative is converted to the corresponding hemi-calcium salt. Most preferably, greater than about 95% of the statin ester derivative is converted to the corresponding hemi-calcium salt.
  • the calcium hydroxide fulfills two roles. It functions as a basic catalyst for hydrolysis of the ester and supplies calcium ions for forming the hemi-calcium salt.
  • Another significant practical advantage of the process is that the amount of calcium hydroxide does not have to be as carefully controlled as the amount of sodium hydroxide and calcium chloride/acetate used in other processes which, in contrast to the present invention, involve a sequential process of hydrolyzing the ester derivative with NaOH followed by displacement of the sodium ion with calcium ions.
  • the statin ester derivative may be provided in pure form or in mixture with other statin ester derivatives.
  • statin ester derivative is dissolved or suspended preferably in a mixed solvent comprising a Ci- C 4 alcohol and water.
  • Preferred alcohols are ethanol and isopropyl alcohol ("IP A") and a preferred solvent mixture contains about 5% to about 15% water in ethanol or IP A, more preferably about 10% water and about 90% ethanol (v/v) or IPA.
  • IP A isopropyl alcohol
  • a preferred solvent mixture contains about 5% to about 15% water in ethanol or IP A, more preferably about 10% water and about 90% ethanol (v/v) or IPA.
  • Whether the statin ester derivative dissolves in the mixed solvent depends upon such factors as the choice of C ⁇ -C alcohol, the proportion of water, the temperature and the purity of the statin ester derivative.
  • Calcium hydroxide is then suspended in the solvent and the base hydrolysis reaction mixture is maintained until the statin ester derivative has been consumed.
  • statin ester derivative may be monitored by any conventional means such as TLC, HPLC and NMR. After the statin ester derivative has been consumed, statin hemi-calcium is recovered from the base hydrolysis reaction mixture by conventional means. It is unnecessary to add another source of calcium to provide a Ca 2+ ion for the atorvastatin hemi-calcium salt.
  • statin ester derivative is added in an amount sufficient to provide about 10 mmoles L “1 to about 1 mole L "1 of the mixed solvent.
  • the ester derivative 1 Preferably, about 1 equivalent to about 6 equivalents of calcium hydroxide with respect to the ester derivative 1 is used. More preferably, from about 1 to about 2 equivalents is used.
  • Calcium hydroxide is only sparingly soluble in the C ⁇ -C 4 alcohol: water mixed solvent and only a minor proportion of it will be in solution available to catalyze the hydrolysis at any one time.
  • a phase transfer catalyst may be added to increase the solubility of the calcium hydroxide.
  • Phase transfer catalysts are well known in the art and include, for instance, tetra-n-butylammonium bromide (“TBAB”), benzyltriethylammonium chloride (“TEBA”), tetra-n-butylammonium chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium iodide, tetra-ethylammonium chloride, benzyltributylammonium chloride, benzyltributylammonium bromide, benzyltriethylammonium bromide, tetramethylammonium chloride and polyethylene glycol.
  • TBAB tetra-n-butylammonium bromide
  • TEBA benzyltriethylammonium chloride
  • TBAB tetra-n-butylammonium bromide
  • TEBA benzyl
  • phase transfer catalyst is TBAB.
  • the phase transfer catalyst should be used in a substoichiometric amount, preferably from about 0.05 to about 0.25 equivalents, more preferably about 0.1 equivalents, with respect to statin ester derivative.
  • the mixture may be heated to up to the reflux temperature of the mixed solvent in order to accelerate the reaction.
  • a preferred temperature range is at an elevated temperature of from about 40°C to about 70°C.
  • statin hemi-calcium or solvate thereof is recovered from the base hydrolysis reaction mixture.
  • the reaction mixture is preferably filtered to remove excess suspended calcium hydroxide.
  • the reaction mixture preferably is filtered while hot to prevent precipitation of statin hemi-calcium on the calcium hydroxide filtercake.
  • statin hemi-calcium may be recovered from the filtrate by precipitation.
  • statin hemi-calcium is caused to precipitate from the filtrate by slow addition of water.
  • a volume of water roughly equivalent to the volume of the filtrate is added over about an hour's time.
  • the slow water addition is also conducted at elevated temperatures, e.g. from about 40°C to about 65 °C.
  • Precipitating statin hemi-calcium by slow water addition yields statin hemi-calcium in a crystalline form and prevents formation of a gelatinous precipitate.
  • statin hemi-calcium may be recovered by any conventional means.
  • the recovered statin hemi-calcium may be used as an active ingredient to formulate a pharmaceutical product.
  • the filtering characteristics and purity of the statin hemi-calcium may be further improved by redissolving the crystalline product in the aqueous alcohol reaction mixture by heating to a temperature sufficient to cause all the precipitate to dissolve, resulting in a clear solution.
  • the solution is preferably cooled slowly over several hours and held, preferably at ambient temperature, until no more crystals are observed to form.
  • the statin hemi-calcium or solvate thereof may be used as an active ingredient in a pharmaceutical product.
  • Statins are sometimes prepared through an intermediate in which one or both of the hydroxyls in the pentanoic acid diol group (open-ring form) or the hydroxyl of the lactone (closed-ring form) are protected via a hydrolyzable protecting group and the carboxyl group is protected via an ester derivative as described hereinabove.
  • a hydrolyzable protecting group for example, U.S. Pat. No. 5,260,440, incorporated herein by reference, uses a silyl protecting group during synthesis of rosuvastatin.
  • U.S. Pat. Nos. 6,002,021 and 4,444,784, incorporated herein by reference use a silyl protecting group during the synthesis of simvastatin. Brower, P.L. et al. Tet. Lett.
  • statin ester derivatives may be converted in accordance with the present invention to the corresponding hemi-calcium salt.
  • the present invention is directed to a process for preparing a calcium salt of a statin having the formula:
  • R represents an organic radical, comprising contacting an ester derivative of the statin selected from the group consisting of:
  • Ri is a Ci to a C 8 alkyl group
  • R , R 3 and i each independently represent hydrogen, or the same or different hydrolyzable protecting group, or R 2 and R 3 , together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group.
  • the protecting group used is preferably hydrolyzable under acidic or basic conditions.
  • Preferred protecting groups R 2> R 3 and R» in accordance with this embodiment of the present invention include, for example, silyl groups, with trialkylsilyl and alkyldiarylsilyl being more preferred, and with t-butyl-dimethyl-silyl being the most preferred; and, cyclic protecting groups such that R 2 and R 3 form, for example, a dioxane.
  • U.S. Pat. No. 6,294,680 discloses additional protecting groups used in the synthesis of statins, particularly simvastatin.
  • cyclic protecting groups include a dioxane, a cyclic sulfate, a cyclic phosphate or borylidene, which are optionally substituted with alkyl and aryl groups.
  • Other protecting groups include boronic acid, disclosed in WO 95/13283, incorporated herein by reference and esterification with an acetic anhydride, disclosed in U.S. Pat. No. 5,159,104, incorporated herein by reference.
  • U.S. Pat. No. 6,100,407, incorporated herein by reference discloses additional protecting groups.
  • the protecting groups disclosed in these references may be used in accordance with the present invention. It has surprisingly been found that a silyl group can be hydrolyzed and removed by contact with calcium hydroxide.
  • silyl group allows for removal of the protecting group and conversion of the ester to a calcium salt in one step, in the same solvent.
  • the use of calcium hydroxide eliminates the need for a separate step of acid hydrolysis of the silyl protecting group with, e.g., a hydrogen halide such as hydrogen fluoride, to remove the protecting group, as required by the processes of U.S. Pat. No.
  • the process of the present invention applies to any statin with a silyl or other protecting group R 2 ⁇ R 3 and P capable of being hydrolyzed by calcium hydroxide.
  • the protected rosuvastatin disclosed in U.S. Pat. No. 5,260,440 e.g., can be used, with a modification of reducing the ketone to obtain hydrogen as R 2 .
  • the silyl protected simvastatin disclosed in U.S. Pat. Nos. 4,444,784 and 6,002,021 can also be used.
  • Some of the protecting groups are best hydrolyzed under acidic conditions.
  • an acid catalyst is added to hydrolyze the protecting group.
  • acid catalysts include acetic acid, trifluoroacetic acid, ?-toluenesulfonic acid, zinc bromide and hydrochloric acid or other hydrogen halide, with acetic acid and hydrochloric acid being preferred.
  • the resulting diol ester is then converted to the calcium salt by contact with calcium hydroxide.
  • the process can also be carried out in one pot.
  • the diol-ester is formed as described above, and is then reacted with calcium hydroxide to form atorvastatin hemi-calcium in the same pot, without changing solvent.
  • a preferred solvent is a mixture of water and a Ci to a C 4 alcohol, with ethanol being preferred.
  • a preferred pH for the reaction is less than about 3, more preferably less than about 1.
  • a preferred protecting group that is removed with an acid catalyst is an acetonide, i.e., a compound in which the diol forms a cyclic hydrolyzable protecting group, i.e., a dioxane.
  • any acetone formed during the reaction of the acetonide with the acid catalyst is removed, e.g., by evaporation under reduced pressure.
  • compositions may be prepared as medicaments to be administered orally, parenterally, rectally, transdermally, bucally, or nasally.
  • suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or gelatin capsules, sub-lingual tablets, syrups and suspensions.
  • Suitable forms of parenteral administration include an aqueous or non-aqueous solution or emulsion, while for rectal administration suitable forms for administration include suppositories with hydrophilic or hydrophobic vehicle.
  • the invention provides suitable transdermal delivery systems known in the art, and for nasal delivery there are provided suitable aerosol delivery systems known in the art.
  • compositions of the present invention contain statin hemicalcium, particularly atorvastatin hemicalcium, rosuvastatin hemicalcium, pitavastatin hemicalcium, simvastatin hemicalcium and lovastatin hemicalcium.
  • the pharmaceutical compositions of the present invention can contain one or more excipients. Selection of excipients and the amounts to use can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field. U.S. Pat. No. 6,316,460, incorporated herein by reference, and the most recent edition of Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, can be used as a guidance. The dosage and formulation of LIPITOR® (atorvastatin hemi-calcium) and the other pharmaceuticals can also be used as a guidance.
  • the oily product was placed in a mixture of ethanol (100 ml) and water (20 ml).
  • a mixture of calcium hydroxide (5.5 eq., 6.22g, 84.0 10 "3 mmole) and 5% (w/w of the dioxane ester derivative) tetrabutyl ammonium bromide (0.46 g) was added.
  • the mixture was heated to a temperature of about 45° C for about 3 hours until the reaction was completed. While the mixture was hot, filtration was done under vacuum to remove the excess calcium hydroxide.
  • the mixture was then cooled to ambient temperature, after which, while stirring, water (200 ml) was added. After about 20 minutes of stirring at ambient temperature, the reaction was completed.
  • the aqueous layer was extracted with dichloromethane (3x10 ml), whereas the organic layer was dried with sodium sulfate and filtrated. The organic layer was then evaporated under reduced pressure to give the resulting product (150 mg). Based on HPLC analysis, the resulting product was a mixture of atorvastatin and atorvastatin lactone in the ratio of 57 :43 , respectively.
  • the resulting solution was evaporated to dryness and the traces of acetic acid were removed by azeotropic distillation with toluene (3x15 ml) to obtain a powder. Based on HPLC analysis, the product was a mixture of atorvastatin and atorvastatin lactone in the ratio of 54:46, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des procédés permettant de préparer un sel calcique d'une statine à partir d'un dérivé d'ester ou d'un dérivé d'ester protégé de la statine au moyen d'hydroxyde de calcium. Le dérivé d'ester ou le dérivé d'ester protégé est mis en contact avec l'hydroxyde de calcium pour obtenir le sel calcique. Les statines préférées sont la rosuvastatine, la pitavastatine et l'atorvastatine, la simvastatine et la lovastatine. Dans les procédés qui commencent avec un dérivé d'ester de statine protégé, le groupe protecteur est soit hydrolysé pendant la formation du sel par contact avec l'hydroxyde de calcium, soit mis en contact avec un catalyseur acide, puis avec l'hydroxyde de calcium.
EP02759374A 2001-08-16 2002-08-16 Procedes permettant de preparer des formes salines calciques de statines Withdrawn EP1425287A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31281201P 2001-08-16 2001-08-16
US312812P 2001-08-16
US10/037,412 US6528661B2 (en) 2000-11-16 2001-10-24 Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US37412 2001-10-24
PCT/US2002/026012 WO2003016317A1 (fr) 2001-08-16 2002-08-16 Procedes permettant de preparer des formes salines calciques de statines

Publications (2)

Publication Number Publication Date
EP1425287A1 true EP1425287A1 (fr) 2004-06-09
EP1425287A4 EP1425287A4 (fr) 2005-09-07

Family

ID=26714105

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02759374A Withdrawn EP1425287A4 (fr) 2001-08-16 2002-08-16 Procedes permettant de preparer des formes salines calciques de statines

Country Status (17)

Country Link
EP (1) EP1425287A4 (fr)
JP (2) JP4188826B2 (fr)
CN (1) CN100430405C (fr)
AU (1) AU2002324715B2 (fr)
CA (1) CA2450820C (fr)
CZ (1) CZ2004337A3 (fr)
HR (1) HRPK20040255B3 (fr)
HU (1) HUP0500616A3 (fr)
IL (2) IL160077A0 (fr)
IS (1) IS7148A (fr)
MX (1) MXPA04001451A (fr)
NO (1) NO20041082L (fr)
NZ (1) NZ529913A (fr)
PL (1) PL370407A1 (fr)
SK (1) SK1402004A3 (fr)
TR (1) TR200302281T2 (fr)
WO (1) WO2003016317A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
NZ526022A (en) * 2000-11-16 2005-04-29 Teva Pharma Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (fr) 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2412012C (fr) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Matrice extracellulaire resorbable contenant du collagene i et du collagene ii pour la reconstruction de cartilage
BR0215644A (pt) 2002-03-18 2004-12-21 Biocon Ltd Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado
EP1585736A2 (fr) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Procede de preparation de rosuvastatine
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CA2513837A1 (fr) * 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Formes cristallines de calcium de pitavastatine
SI1631533T1 (sl) 2003-04-22 2009-08-31 Bicon Ltd Nov postopek za stereoselektivno redukcijo beta - ketoestrov
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
BRPI0412786A (pt) * 2003-07-25 2006-09-26 Avecia Pharmaceuticals Ltd processo para a preparação de um composto, e, composto
AU2003269477A1 (en) * 2003-08-26 2005-03-10 Biocon Limited Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt
EP1816126A1 (fr) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Procédé pour la préparation de rosuvastatine calcique
WO2005023778A2 (fr) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Procede de preparation de sels calciques de rosuvastatine
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005026107A1 (fr) 2003-09-18 2005-03-24 Biocon Limited Nouveau processus de preparation de tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
EP1678148A1 (fr) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine calcique amorphe
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CA2546894C (fr) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Norme de reference pour la caracterisation de la rosuvastatine
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1711489B1 (fr) * 2003-12-29 2012-12-26 LEK Pharmaceuticals d.d. Procede pour preparer un compose amorphe d'acide (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetique
CZ200486A3 (cs) * 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (fr) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Sels de magnesium amorphes de la rosuvastatine
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
BRPI0514189A (pt) * 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
JP2008515931A (ja) 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
CN100371709C (zh) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法
WO2007125547A2 (fr) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Nouveau procédé faisant intervenir des statines et leurs sels acceptables sur le plan pharmaceutique
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (fr) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Procédé pour la préparation d'ester méthylique de rosuvastatine
WO2010089770A2 (fr) 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables
EP2526099B1 (fr) 2010-01-18 2016-03-30 MSN Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
EP3178812A1 (fr) * 2010-11-12 2017-06-14 Hetero Research Foundation Nouveaux polymorphes de calcium de pitavastatine
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102875504A (zh) * 2011-07-13 2013-01-16 华南理工大学 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途
CN102302452B (zh) * 2011-09-14 2012-11-21 海南美大制药有限公司 匹伐他汀钙脂质体固体制剂
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
CN106029895B (zh) * 2014-02-06 2021-07-16 株式会社Api 瑞舒伐他汀钙及其中间体的生产方法
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105111173B (zh) * 2015-06-26 2017-06-23 上海应用技术学院 他汀含氟衍生物及其用途
CN105017231B (zh) * 2015-06-26 2018-01-26 上海应用技术学院 多取代吲哚类他汀含氟修饰物及其用途
CN113620871A (zh) 2015-08-05 2021-11-09 株式会社Api 生产匹伐他汀钙的方法
CN111362856B (zh) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 一种利用微反应装置生产阿托伐他汀钙的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
WO2000049014A1 (fr) * 1999-02-17 2000-08-24 Astrazeneca Ab Procede de production de tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2002043667A2 (fr) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. HYDROLYSE D'ESTERS D'ACIDE [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE AU MOYEN D'HYDROXYDE DE CALCIUM HYDROXIDE
WO2002043732A1 (fr) * 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes
WO2002051804A1 (fr) * 2000-12-27 2002-07-04 Ciba Specialty Chemicals Holding Inc. Formes cristallines d'atorvastatine
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5817443B2 (ja) * 1976-11-02 1983-04-07 三共株式会社 Ｍｌ−２３６ｂ金属塩を主成分とする高脂血症治療剤
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US5669156A (en) * 1996-08-28 1997-09-23 Fleetwood Systems, Inc. Can end curing system with magnetic fanning and belt conveying
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
EP1161236A1 (fr) * 1999-03-08 2001-12-12 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
AU2007205725A1 (en) * 2000-11-30 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
WO2000049014A1 (fr) * 1999-02-17 2000-08-24 Astrazeneca Ab Procede de production de tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2002043667A2 (fr) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. HYDROLYSE D'ESTERS D'ACIDE [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE AU MOYEN D'HYDROXYDE DE CALCIUM HYDROXIDE
WO2002043732A1 (fr) * 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes
WO2002051804A1 (fr) * 2000-12-27 2002-07-04 Ciba Specialty Chemicals Holding Inc. Formes cristallines d'atorvastatine
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO03016317A1 *
WATANABE M ET AL: "Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY 199702 GB LNKD- DOI:10.1016/S0968-0896(96)00248-9, vol. 5, no. 2, February 1997 (1997-02), pages 437-444, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
HRP20040255A2 (en) 2004-08-31
SK1402004A3 (sk) 2005-01-03
JP4188826B2 (ja) 2008-12-03
IL160077A (en) 2007-10-31
PL370407A1 (en) 2005-05-30
IS7148A (is) 2004-02-11
TR200302281T2 (tr) 2004-09-21
WO2003016317A1 (fr) 2003-02-27
IL160077A0 (en) 2004-06-20
CN1543468A (zh) 2004-11-03
CA2450820A1 (fr) 2003-02-27
CN100430405C (zh) 2008-11-05
AU2002324715B2 (en) 2009-03-12
HRPK20040255B3 (en) 2006-02-28
HUP0500616A2 (hu) 2005-11-28
MXPA04001451A (es) 2005-02-17
NZ529913A (en) 2005-03-24
JP2009024008A (ja) 2009-02-05
HUP0500616A3 (en) 2011-07-28
NO20041082L (no) 2004-03-15
JP2005500382A (ja) 2005-01-06
CZ2004337A3 (cs) 2005-01-12
CA2450820C (fr) 2011-03-15
EP1425287A4 (fr) 2005-09-07

Similar Documents

Publication Publication Date Title
US6777552B2 (en) Processes for preparing calcium salt forms of statins
AU2002324715B2 (en) Processes for preparing calcium salt forms of statins
AU2002324715A1 (en) Processes for preparing calcium salt forms of statins
US6528661B2 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
WO2007132482A2 (fr) Nouveau procédé de synthèse de pitavastatine et de ses sels de qualité pharmaceutique
EP1697338A2 (fr) Procede de preparation de statines a rapport syn anti eleve
WO2006048893A2 (fr) Processus de synthese de composes statine a particules de grande taille
US8497370B2 (en) Processes for preparing amine salts of sildenafil-analogues and use thereof
US20090099371A1 (en) Process for the preparation of amorphous atorvastatin calcium salt
US7851624B2 (en) Triol form of rosuvastatin and synthesis of rosuvastatin
EP2075246A1 (fr) Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
EP2373609B1 (fr) Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines
EP2327682A1 (fr) Utilisation de composés amphiphiles pour la crystallisation controlée de statines et d'intermediaires de statines.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050725

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 9/00 B

Ipc: 7A 61K 31/4965 B

Ipc: 7A 61K 31/4418 B

Ipc: 7A 61K 31/404 B

Ipc: 7A 61K 31/351 B

Ipc: 7A 61K 31/47 B

Ipc: 7A 61K 31/40 B

Ipc: 7A 61K 31/22 B

Ipc: 7C 07D 309/30 B

Ipc: 7C 07D 239/42 B

Ipc: 7C 07D 215/14 B

Ipc: 7C 07D 213/55 B

Ipc: 7C 07D 209/24 B

Ipc: 7C 07C 51/09 B

Ipc: 7C 07D 207/24 A

17Q First examination report despatched

Effective date: 20080812

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130104